Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Wed, 24.04.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, April 24, 2024
MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced th [ … ]
Thu, 11.04.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, April 11, 2024
MorphoSys’ Management Board and Supervisory Board Recommend Shareholders Accept Public Takeover Offer by Novartis
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion
Shareholders benefit from attractive premium of 94% and 142% on the volume-weig [ … ]
Fri, 22.03.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 22, 2024
MorphoSys Announces U.S. Antitrust Clearance of Proposed Acquisition by Novartis Under HSR Act
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the pro [ … ]
Wed, 13.03.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, March 13, 2024
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
- Entered into Business Combination Agreement to be acquired by Novartis for € 68.00 per share in cash or € 2.7 billion equity value
- Sold all tafasitamab rights worldwide to Incyte
- P [ … ]
Thu, 07.03.2024
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, March 07, 2024
Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the financial year 2023 on March 13, 2024, at 09:00 pm CET (08:00 pm GMT; 04:00 pm EDT).
MorphoSys' Management team will host a con [ … ]
Mon, 05.02.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, February 5, 2024
MorphoSys Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value
Tafasitamab sold to Incyte
Novartis to launch a voluntary public takeover offer for all MorphoSys shares at a price of
€ 68.00 per share in cash
Shareholders benefi [ … ]
Mon, 05.02.2024
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, February 5, 2024
Ad hoc: MorphoSys AG Enters into Business Combination Agreement to be Acquired by Novartis for € 2.7 Billion Equity Value and into Purchase Agreement with Incyte for the Sale of Tafasitamab
M [ … ]
Tue, 30.01.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 30, 2024
MorphoSys Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Preliminary 2023 Monjuvi U.S. net product sales of US$ 92.0 million (€ 85.0 million) and preliminary gross margin for Monjuvi U.S. net prod [ … ]
Tue, 30.01.2024
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, January 30, 2024
Ad hoc: MorphoSys AG Reports Preliminary 2023 Monjuvi U.S. Net Product Sales and Gross Margin, Provides 2024 Financial Guidance and Reduces Financial Liability
Preliminary 2023 Monjuvi U.S. net pro [ … ]
Mon, 08.01.2024
MorphoSys AG
Media Release
Planegg/Munich, Germany, January 8, 2024
MorphoSys to Present at the 42nd Annual J.P. Morgan Healthcare Conference
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that Jean-Paul Kress, M.D., Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 3:00 p.m. [ … ]